Pharvaris NV Insider Holds Steady: CEO’s 55,000-Share Retention Signals Confidence in B2 Antagonist Pipeline
Pharvaris insider Souverijns keeps 55k shares, showing strong confidence in its B2 antagonist pipeline and a long‑term growth outlook.
10 minutes to read